Held May 14 at ISPOR 2025 in Montreal, this session took a hard look at the ripple effects of drug price controls, including recent US policy shifts like the IRA and President Trump’s Executive Order introducing International Reference Pricing.
As the United States continues to drive roughly 70% of global pharmaceutical revenues, the implications of price setting on research and development investment and innovation were at the forefront of this crucial discussion.
The session covered:
- The unintended consequences of setting prices too low
- The difficulty in aligning policy with innovation incentives
- The rationale behind International Reference Pricing—and what alternatives exist
- What early data is already telling us about the impact of the IRA
ISPOR 2025’s Opening Plenary ignited a vital conversation on the future of drug pricing—highlighting what’s at stake for patients, payers, and the pharmaceutical industry.
Moderator
- Gregory Daniel, MPH, RPh, PhD
Eli Lilly and Company, Washington, DC, United States
Speakers
- Virginia Lee Acha, BA, MPhil, DPhil
Merck, London, United Kingdom - Graham Cookson, MSc, PhD
Office of Health Economics, London, United Kingdom - Darius Lakdawalla, PhD
University of Southern California, Los Angeles, CA, United States - Sean D Sullivan, PhD
University of Washington, Seattle, WA, United States
Stay ahead of the curve on evolving drug pricing policy, complete the quick form to access the full Plenary session recording.